These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18349389)

  • 1. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
    Owzar K
    J Clin Oncol; 2008 Mar; 26(9):1400-1. PubMed ID: 18349389
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
    Chu E
    Clin Colorectal Cancer; 2008 May; 7(3):162. PubMed ID: 18621632
    [No Abstract]   [Full Text] [Related]  

  • 4. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 5. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
    Li J
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
    [No Abstract]   [Full Text] [Related]  

  • 6. K-Ras mutations are changing practice in advanced colorectal cancer.
    McNeil C
    J Natl Cancer Inst; 2008 Dec; 100(23):1667-9. PubMed ID: 19033564
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
    Moroni M; Veronese S; Benvenuti S; Marrapese G; Sartore-Bianchi A; Di Nicolantonio F; Gambacorta M; Siena S; Bardelli A
    Lancet Oncol; 2005 May; 6(5):279-86. PubMed ID: 15863375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic colorectal cancer: is there one standard approach?
    Saltz LB
    Oncology (Williston Park); 2005 Aug; 19(9):1147-54; discussion 1154, 1157-8, 1160. PubMed ID: 16255132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab in colon cancer.
    Costa AF; Sander GB; Picon PD
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
    [No Abstract]   [Full Text] [Related]  

  • 10. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 11. ERBITUX as a single agent and in combination in colorectal carcinoma.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
    [No Abstract]   [Full Text] [Related]  

  • 12. Cetuximab in colon cancer.
    Martin MJ
    N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
    [No Abstract]   [Full Text] [Related]  

  • 13. [Utilizing synergism].
    Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
    [No Abstract]   [Full Text] [Related]  

  • 14. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
    Vincenzi B; Santini D; Tonini G
    J Clin Oncol; 2006 Apr; 24(12):1957; author reply 1957-8. PubMed ID: 16622275
    [No Abstract]   [Full Text] [Related]  

  • 15. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
    Saltz LB
    Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cetuximab].
    Takiuchi H
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
    Hebbar M; Di Fioré F; Conroy T; Giraud C; Gasnault L; Fournier C; Péreira R; Bouché O; Fournier P; Deligny N; Joly JP; Maes P; Rad E; Michel P; Adenis A
    Oncology; 2007; 73(3-4):185-91. PubMed ID: 18418011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Present status of chemotherapy for colorectal cancer in countries outside of Japan].
    Doi T; Ohtsu A
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():368-73. PubMed ID: 14574915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.